These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 38338658)

  • 1. γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy.
    Papadakos SP; Arvanitakis K; Stergiou IE; Koutsompina ML; Germanidis G; Theocharis S
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner.
    Yi Y; He HW; Wang JX; Cai XY; Li YW; Zhou J; Cheng YF; Jin JJ; Fan J; Qiu SJ
    J Hepatol; 2013 May; 58(5):977-83. PubMed ID: 23262246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of peripheral CD3
    Zhang S; Li L; Liu C; Pu M; Ma Y; Zhang T; Chai J; Li H; Yang J; Chen M; Kong L; Xia T
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):365. PubMed ID: 39052085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low counts of γδ T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection.
    Cai XY; Wang JX; Yi Y; He HW; Ni XC; Zhou J; Cheng YF; Jin JJ; Fan J; Qiu SJ
    Asian Pac J Cancer Prev; 2014; 15(2):775-80. PubMed ID: 24568494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2
    He W; Hu Y; Chen D; Li Y; Ye D; Zhao Q; Lin L; Shi X; Lu L; Yin Z; He X; Gao Y; Wu Y
    Clin Transl Med; 2022 Apr; 12(4):e800. PubMed ID: 35390227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
    Aggeletopoulou I; Kalafateli M; Triantos C
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
    Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
    Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.
    Hoh A; Dewerth A; Vogt F; Wenz J; Baeuerle PA; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2013 Jan; 33(1):127-36. PubMed ID: 23088518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
    Wang J; Ling S; Ni J; Wan Y
    BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of new potential antigen recognized by γδT cells in hepatocellular carcinoma.
    Xi X; Guo Y; Zhu M; Qiu F; Lei F; Li G; Du B
    Cancer Immunol Immunother; 2021 Jul; 70(7):1917-1927. PubMed ID: 33399933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
    Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
    Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatic stellate cells inhibit the proliferation and invasion of HepG2 hepatocellular carcinoma via activating γδ T cells].
    Fan K; Liao R; Xie Y; Peng C; Du C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):870-874. PubMed ID: 28712391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of adoptive cell therapy in hepatocellular carcinoma.
    Wu D; Li Y
    Immunology; 2023 Dec; 170(4):453-469. PubMed ID: 37435926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γδ T cells: The potential role in liver disease and implications for cancer immunotherapy.
    Ren H; Li W; Liu X; Zhao N
    J Leukoc Biol; 2022 Dec; 112(6):1663-1668. PubMed ID: 36098208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
    Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
    Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
    Bozward AG; Warricker F; Oo YH; Khakoo SI
    Front Immunol; 2021; 12():643310. PubMed ID: 33995362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
    Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
    Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The capability of heterogeneous γδ T cells in cancer treatment.
    Yan W; Dunmall LSC; Lemoine NR; Wang Y; Wang Y; Wang P
    Front Immunol; 2023; 14():1285801. PubMed ID: 38077392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. γδ T cells: origin and fate, subsets, diseases and immunotherapy.
    Hu Y; Hu Q; Li Y; Lu L; Xiang Z; Yin Z; Kabelitz D; Wu Y
    Signal Transduct Target Ther; 2023 Nov; 8(1):434. PubMed ID: 37989744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.